Study aim: The aim of this study is to determine the effect of nanocurcumin supplementation on serum level of hs-CRP, the severity of symptoms and length of hospital stay in patients with COVID-19. Design: The present study is a parallel randomized clinical trial with a control group. Settings and conduct: Patients will be randomly divided to two groups of 24: intervention group (receiving nanocurcumin supplement) and control group (receiving placebo). Height, weight, and waist circumference will be measured and questionnaires for severity of infection symptoms of upper and lower respiratory tract will be filled out. Ten milliliter fasting blood will be taken from all patients at the beginning and end of the intervention. Participants/Inclusion and exclusion criteria: Patients aged 30 to 70 years with confirmation of COVID-19 (having a positive PCR test or involved lung CT-scan) who do not require ICU admission will be included in the study. Patients with a history of chemotherapy, organ transplants, malignancies, dialysis, CABG, liver failure, HIV, heart attack and stroke in the past 3 months, uncontrolled diabetes, known food allergies, and people with BMI over 40 and pregnant and lactating women will not be included in the study. Intervention groups: The intervention group will receive 4 capsules daily, each containing 40 mg of nanocurcumin, and the control group will receive 4 placebo capsules daily, which is completely similar to the nanocurcumin supplement, for 6 days. Main outcome variables: hs-CRP, recovery percentage, percentage of oxygen saturation, severity of infection symptoms of upper and lower respiratory tract, CBC